Market Overview

UPDATE: Credit Suisse Initiates Chipotle With Outperform, $870 Tgt As Firm Notes Co. 'has returned to a narrative of growth rather than recovery, with on-trend initiatives that well position the company to appeal to its target base and outperform peers'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for CMG

DateFirmActionFromTo
Jul 2019Initiates Coverage OnSell
Jul 2019MaintainsEqual-Weight
Jul 2019MaintainsOverweight

View More Analyst Ratings for CMG
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Initiation Analyst Ratings

 

Related Articles (CMG)

Latest Ratings

StockFirmActionPT
SKXMaintains44.0
HYMaintains66.0
MSFTMaintains160.0
SKXUpgrades
WLTWMaintains208.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Tuesday's Market Minute: FedEx Fights Back

No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails